Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy
BackgroundAtezolizumab has recently demonstrated improved prognosis in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) who are not eligible for treatment with a platinum-containing regimen, as observed in a randomized phase 3 clinical trial. This study aims to evaluate the co...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2025.1349645/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|